No recurrence of a neuroleptic malignant syndrome under quetiapine.
D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003975:Diazepam / Q000009:adverse effects* / Q000627:therapeutic use; D003987:Dibenzothiazepines / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006220:Haloperidol / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D009459:Neuroleptic Malignant Syndrome / Q000209:etiology* / Q000517:prevention & control*; D011618:Psychotic Disorders / Q000188:drug therapy*; D000069348:Quetiapine Fumarate; D055502:Secondary Prevention
D000927:Anticonvulsants; D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D000069348:Quetiapine Fumarate; D006220:Haloperidol; D003975:Diazepam